TRABECTEDIN


Trade Names	YONDELIS
Synonyms	ET-743 Ecteinascidin 743 Ecteinascidins trabectedin NSC-648766 Trabectedin Yondelis
Status
Molecule Category	UNKNOWN
ATC	L01CX01
UNII	ID0YZQ2TCP
EPA CompTox	DTXSID2046880


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	PKVRCIRHQMSYJX-AIFWHQITSA-N
Smiles	COc1cc2c(cc1O)CCN[C@]21CS[C@@H]2c3c(OC(C)=O)c(C)c4c(c3[C@H](COC1=O)N1[C@@H]2[C@H]2c3c(cc(C)c(OC)c3O)C[C@@H]([C@@H]1O)N2C)OCO4
InChI	InChI=1S/C39H43N3O11S/c1-16-9-20-10-22-37(46)42-23-13-50-38(47)39(21-12-25(48-5)24(44)11-19(21)7-8-40-39)14-54-36(30(42)29(41(22)4)26(20)31(45)32(16)49-6)28-27(23)35-34(51-15-52-35)17(2)33(28)53-18(3)43/h9,11-12,22-23,29-30,36-37,40,44-46H,7-8,10,13-15H2,1-6H3/t22-,23-,29+,30+,36+,37-,39+/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C39H43N3O11S
Molecular Weight	761.85
AlogP	3.41
Hydrogen Bond Acceptor	15.0
Hydrogen Bond Donor	4.0
Number of Rotational Bond	3.0
Polar Surface Area	168.72
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	54.0

Bioactivity

Mechanism of Action	Action	Reference
DNA inhibitor	INHIBITOR	DailyMed

Assay Description	Organism	Bioactivity	Reference
Effect on cell cycle distribution in Chinese hamster homologous recombination repair XRCC3 gene deficient irs1SF cells after 1 hr followed by post incubation in drug-free media	Cricetulus griseus	6.0 nM
Cytotoxicity against mouse L1210 cells	Mus musculus	0.0005 ug.mL-1

Related Entries

Cross References

Resources	Reference
ChEBI	84050
ChEMBL	CHEMBL450449
DrugBank	DB05109
DrugCentral	4633
FDA SRS	ID0YZQ2TCP
Human Metabolome Database	HMDB0015609
Guide to Pharmacology	2774
PDB	ECT
PharmGKB	PA165958349
PubChem	108150
SureChEMBL	SCHEMBL12119916
ZINC	ZINC000150338708

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).